Skip to main content
Skip to section navigation
Skip to footer
Home
About
Overview
Management Team
Board of Directors
Science Advisors
Technology
Overview
RAMP™ Drug Innovation Engine
Pipeline
Overview
Risvodetinib (IkT-148009) for Parkinson’s Disease and GI complications
IkT-001Pro for CML
IkT-001Pro for PAH
Collaborative Programs
Partnering with Inhibikase
Scientific Publications
Clinical Trials
News
Press Releases
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
Governance
Contact
Careers
All SEC Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
Events
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Board Diversity Matrix
Filing Type:
View All
10-K
10-K/A
10-Q
3
4
424B3
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DEFR14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
PRE 14A
RW
S-1
S-1/A
S-1MEF
S-3
S-8
SC 13D
SC 13G
SC 13G/A
SC 14F1
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2018
Date
Form
Description
PDF
XBRL
Pages
06/02/21
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Documents
expand_more
EX-1.1
EX-4.19
310
06/01/21
8-K
Current report filing
Documents
expand_more
EX-99.1
33
05/18/21
4
Statement of changes in beneficial ownership of securities
2
05/17/21
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Documents
expand_more
EX-31.1
EX-31.2
EX-32.1
EX-32.2
28
04/30/21
DEFA14A
Additional definitive proxy soliciting materials and Rule 14(a)(12) material
3
04/30/21
DEF 14A
Definitive proxy statements
50
04/01/21
8-K
Current report filing
Documents
expand_more
EX-99.1
9
03/31/21
10-K
Annual report pursuant to Section 13 and 15(d)
Documents
expand_more
EX-4.19
EX-21.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
136
03/23/21
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
3
02/11/21
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
3
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
Page
14
Page
15
Page
16
Page
17
Page
18
Page
19
Page
20
Page
21
Page
22
Page
23
Next Page
arrow_forward
Select a page:
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Email Alerts
Contacts
RSS News Feed